Sequenom Licenses Rights to Macular Degeneration Genetic Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today said that it has licensed from Optherion exclusive worldwide rights to intellectual property covering diagnostic tests for genetic predisposition to late-stage age-related macular degeneration.

The licensing deal covers IP for AMD-related genetic variants that have been confirmed in multiple clinical studies around the world, according to Sequenom.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.